Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Korro Bio ( (KRRO) ) has provided an announcement.
On January 27, 2026, Korro Bio, Inc. held a virtual Analyst Day where management presented KRRO-121, a GalNAc-conjugated antisense oligonucleotide designed to edit glutamine synthetase (GS) mRNA in the liver, creating a more stable GS variant to enhance ammonia clearance. The company highlighted preclinical data showing that KRRO-121 stabilized GS and improved ammonia control in human cell models of urea cycle disorders, underscoring its potential as a first-in-class, pan-urea cycle disorder treatment that could relax dietary restrictions and address broader ammonia-driven conditions such as hepatic encephalopathy; Korro also indicated plans to submit a regulatory filing in the second half of 2026 to enable a first-in-human trial, marking a key step in advancing its RNA-editing platform and expanding its presence in the genetic medicines space.
The most recent analyst rating on (KRRO) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Korro Bio stock, see the KRRO Stock Forecast page.
Spark’s Take on KRRO Stock
According to Spark, TipRanks’ AI Analyst, KRRO is a Neutral.
The score is held down primarily by very large ongoing losses and heavy cash burn despite improving revenue, indicating continued reliance on external funding. Technicals also remain weak with the stock below key longer-term moving averages and negative MACD. Corporate events add uncertainty due to trial termination and a paused collaboration, while the balance sheet’s moderate leverage provides only partial support.
To see Spark’s full report on KRRO stock, click here.
More about Korro Bio
Korro Bio, Inc. is a biopharmaceutical company developing RNA-editing–based genetic medicines aimed at modulating protein function without permanently altering DNA. Its pipeline targets rare and highly prevalent diseases, with a focus on liver-directed therapies and conditions driven by dysregulated pathways such as hyperammonemia, urea cycle disorders and other ammonia-related diseases.
Average Trading Volume: 515,135
Technical Sentiment Signal: Sell
Current Market Cap: $101M
Find detailed analytics on KRRO stock on TipRanks’ Stock Analysis page.